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Hutchinson-Gilford progeria syndrome is a rare childhood genetic disorder with features of accelerated
aging. In this issue, Hernandez et al. observe decreased Wnt signaling and extracellular matrix gene expres-
sion in a murine model of the disease, suggesting potential therapeutic strategies and further emphasizing
the nuclear envelope’s role in signal transduction.‘‘Laminopathies’’ are a diverse group of
diseases arising from mutations in genes
encoding proteins of the nuclear envelope,
particularly LMNA encoding A-type lam-
ins. An emerging picture from the investi-
gation of these diseases and other basic
research is that abnormalities in the
nuclear envelope can lead to alterations
in cell signaling pathways that underlie
pathogenesis (Dauer and Worman, 2009).
For example, a mouse knockin mutation,
corresponding to a LMNA mutation that
causes Emery-Dreifuss muscular dys-
trophy in humans, has been shown to acti-
vate cardiac MAP kinase signaling and
contribute to the development of cardio-
myopathy (Muchir et al., 2007). Different
mutations in LMNA cause other diseases
for which the etiology and pathogenesis
are poorly understood, with one of the
most enigmatic being Hutchinson-Gilford
progeria syndrome (HGPS).
In 1886, Jonathan Hutchinson first
described what is now known as HGPS.
A year later, Hastings Gilford described
a second patient and later introduced
the term progeria. HGPS is an extremely
rare genetic disorder associated with
a characteristic aged appearance very
early in life. Children with HGPS appear
normal at birth but within a year begin to
display the effects of accelerated aging.
As they mature, the disorder causes
children to age about a decade for every
year of their life. On average, death occurs
at the age of 13, with at least 90% of
subjects dying from progressive athero-
sclerosis of the coronary and cerebral
arteries, with tissues such as bone and
skin also prominently affected.
HGPS is a sporadic autosomal domi-
nant disease caused in nearly all casesby a de novo single-base substitution in
codon 608 of exon 11 of LMNA (Eriksson
et al., 2003; De Sandre-Giovannoli et al.,
2003). The LMNA mutation creates
a cryptic splice donor site, resulting in ex-
pression of a truncated prelamin A called
‘‘progerin’’ with a 50-amino acid internal
deletion near the carboxyl-terminus. Prel-
amin A is normally farnesylated on the
cysteine of a CAAX motif located at its
carboxyl-terminus. The prenylated protein
is then recognized by the endoprotease
ZMPSTE24 and cleaved 15 amino acids
away from the fanesylated cysteine. This
cleavage site is deleted from progerin
and hence it remains farnesylated. Even
though no single mechanism has clearly
emerged to explain the complex pheno-
type in HGPS, considerable data suggest
that farnesylated progerin is themolecular
culprit. Treatment with protein farnesyl-
transferase inhibitors reverses aberrant
nuclear shapes that result from progerin
expression and, more importantly,
improves the abnormal phenotypes in
mice with an HGPS mutation in Lmna
(Yang et al., 2006). These fascinating labo-
ratory studies have led to clinical trials of
protein prenylation inhibitors in children
with HGPS. However, progeroid mice
treated with protein farnesyltransferase
inhibitors as well as mice that express
a progerin variant that cannot be farnesy-
lated still have a fairly severe disease
phenotype and die prematurely (Yang
et al., 2008). This emphasizes the need to
decipher more specific molecular mecha-
nisms underlying the HGPS phenotype in
order to understand its pathogenesis and
potentially develop new treatments.
The work presented by Hernandez et al.
(2010) in this issue of Developmental CellDevelopmental Cell 19, Sedescribes abnormal gene expression
and signaling in cells from amurine model
for progeria. Previously, this group led by
Dr. Colin Stewart generated mice with the
LmnaL530P/L530P mutation, which causes
muscular dystrophy and cardiomyopathy
in humans but serendipitously caused
a progeroid phenotype in mice (Mounkes
et al., 2003). In the current study, they
show that this mutation in mice results in
the deletion of exon 9, producing a trun-
cated form of prelamin A that, like pro-
gerin, remains farnesylated, confirming
that these mice represent a valid model
of HGPS. Hernandez et al. (2010) then
describe a downregulation of genes en-
coding extracellular matrix proteins in
cultured cells from adult mice but not
embryonic mice, which can be correlated
with the fact that children with HGPS are
apparently normal at birth and develop
the first symptoms of the disease at 6 to
12 months of age. The authors further
show that altered expression of extracel-
lular matrix genes is associated with defi-
cient Wnt signaling. The defect in Wnt
signaling is an attractive explanation for
some of the progeric phenotypes of the
mouse model, particularly the predomi-
nant abnormalities in bone. Indeed, Wnt
signaling regulates extracellular matrix
composition and is critical for cartilage
development as well as osteoblast and
chondrocyte differentiation during verte-
brate skeletogenesis. While Hernandez
and colleagues (2010) show that bone
density is reduced and that there is
apoptosis inmajor blood vessels proximal
to the heart in LmnaL530P/L530P mice, they
do not include information on Wnt
pathway activity in affected and unaf-
fected tissues. Notably, their mouseptember 14, 2010 ª2010 Elsevier Inc. 355
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children with HGPS, particularly craniofa-
cial deformation, loss of subcutaneous
fat, scleroderma, and alopecia. It would
be extremely interesting to correlate
decreased Wnt signaling with some of
these abnormalities. Notably, Espada
et al. (2008) previously reported reduced
Wnt signaling in skin cells from Zmpste24
null mice, which express unprocessed,
farnesylated prelamin A and develop
a progeroid phenotype.
Hernandez et al. (2010) further demon-
strated that treatment of cultured fibro-
blasts from adult LmnaL530P/L530P mice
with a Gsk-3b inhibitor, which is known
to activate the Wnt effector protein b-cat-
enin, improved survival, and restored
proliferation. They also showed that the
inhibitor improved proliferation of cell
lines from two human subjects with
HGPS. This preliminary observation sug-
gests a potential new therapeutic option
for HGPS. Gsk-3b inhibitors were identi-
fied in the late 1990s and have been
considered for development to treat356 Developmental Cell 19, September 14, 20several diseases, including Alzheimer’s
disease, other neurodegenerative disor-
ders, bipolar affective disorder, and dia-
betes mellitus (Meijer et al., 2004). How-
ever, it is critical to see whether further
studies in animal models of HGPS show
the type of safety and efficacy that would
potentially warrant human clinical trials.
The work in this issue of Developmental
Cell provides further evidence that the
nuclear envelope functions as a critical
signaling node in development and
disease. It further confirms the power of
experimental animal models to decipher
pathogenic mechanisms and identify
potential targets for therapy. Finally, these
results in a mouse model of progeria are
compelling enough to encourage studies
of Wnt signaling in physiological aging.REFERENCES
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In a recent issue of Cell, Ohta et al. report a method of quantitative proteomics coupled with bioinformatic
analysis for the identification of associated components in complex mixtures. Using this approach, they
assayed the protein composition ofmitotic chromosomes, identifying 4029 associated proteins, 562 of which
are previously uncharacterized.The isolation of subcellular fractions and
the identification of their constituents are
instrumental to deciphering how cellular
processes work. Unlike the genome,
however, the proteome varies both tem-
porally and across cell types, making it
challenging to precisely define on a global
scale. Currently, mass spectrometry
provides the most comprehensive andversatile tool in large-scale proteomics.
Combined with classic cell biological
methods of isolation, mass spectrom-
etry-based approaches have successfully
identified hundreds of new protein com-
ponents of specific organelles and sub-
cellular structures ranging frommitochon-
dria to the spliceosome to the mitotic
spindle (Yates et al., 2005). Nevertheless,many key challenges to this approach
remain. For example, the complexity of
the spectra and proteomics data pro-
duced from tens of thousands of peptides
can easily overwhelm the available bioin-
formatics tools. Beyond this, the Achilles’
heel (and perhaps the most severe limita-
tion) of the approach is distinguishing real
constituents of a complex from simple
